Biocon Biologics
Dhairyarajsinh Gohil has extensive experience in the biopharmaceutical industry, currently serving as the QMS lead at Biocon Biologics since May 2022, where responsibilities include overseeing QMS activities for mammalian production of products such as trastuzumab and bevacizumab. Prior to this role, Dhairyarajsinh worked as a Manager at Reliance Industries Limited from June 2017 to May 2022, focusing on novel peptides and biosynthetic materials in the R&D facility. Earlier experience includes positions at Serum Institute of India Pvt. Ltd., where responsibilities encompassed downstream processing and production activities for Hib and MenA vaccines. Academic qualifications include a Master of Science in Biotechnology from Bharati Vidyapeeth, an MBA in Marketing from K.J.S. Education Institute, and a Bachelor of Science in Biotechnology from Deogiri College.
This person is not in any teams
Biocon Biologics
8 followers
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. It has a strong research pipeline of biosimilar molecules across diabetes, oncology, immunology, and other non-communicable diseases. Six molecules from Biocon Biologics’ portfolio have been taken from lab to market in developed markets like United States, EU, Australia, Canada and Japan. With a team of ~ 4,800 people, Biocon Biologics is committed to transforming healthcare and transforming lives by enabling affordable access to millions of patients’ worldwide. Follow-us on Twitter: @BioconBiologics